A recent clinical trial assessing the efficacy of a humanised anti‐IL‐7R monoclonal antibody in subjects with T1D revealed a significant decline in CD4+ and CD8+ effector and central memory T‐cells along with an increase in Tregs.99 Here, CD8A is linked to type 1 diabetes mellitus.